Vanguard Group Inc. Buys 129,337 Shares of Kura Oncology, Inc. $KURA

Vanguard Group Inc. increased its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 2.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 4,948,235 shares of the company’s stock after purchasing an additional 129,337 shares during the quarter. Vanguard Group Inc. owned 5.72% of Kura Oncology worth $32,658,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of KURA. Pallas Capital Advisors LLC bought a new position in Kura Oncology in the 1st quarter valued at $66,000. Flower City Capital bought a new position in shares of Kura Oncology during the 1st quarter worth $79,000. Corton Capital Inc. bought a new position in shares of Kura Oncology during the 4th quarter worth $99,000. Exchange Traded Concepts LLC grew its position in shares of Kura Oncology by 117.8% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,474 shares of the company’s stock worth $115,000 after buying an additional 9,450 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Kura Oncology during the 4th quarter worth $130,000.

Wall Street Analyst Weigh In

KURA has been the subject of a number of analyst reports. JMP Securities decreased their price objective on Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating for the company in a research note on Monday, August 11th. Wall Street Zen upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research note on Sunday, August 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 26th. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a research note on Friday, June 20th. Finally, Barclays decreased their price objective on Kura Oncology from $32.00 to $11.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.10.

Kura Oncology Stock Up 3.7%

Kura Oncology stock opened at $7.86 on Thursday. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $21.57. The business’s 50-day moving average price is $6.35 and its 200 day moving average price is $6.59. The firm has a market cap of $682.25 million, a price-to-earnings ratio of -3.48 and a beta of 0.41.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. As a group, sell-side analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.